Las Vegas, NV -- (SBWIRE) -- 12/12/2013 -- EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more .EquityObserver.com issues a special report on the following stocks: Abraxas Petroleum Corp. (NASDAQ:AXAS), Echo Therapeutics Inc (NASDAQ:ECTE), DARA Biosciences Inc (NASDAQ:DARA), North American Palladium Ltd (USA) (NYSEMKT:PAL)
Abraxas Petroleum Corp. (NASDAQ:AXAS) managed to keep its fall at -7.53% on above-normal volume of 3.48M shares. The stock settled at $3.07 after floating in a range of $3.05 to $3.34. Its latest price has reached market capitalization of $285.09 million. Its 52-week range has been $1.82 to $3.96. Abraxas Petroleum Corporation is an independent energy company primarily engaged in the acquisition, exploitation, development and production of oil and gas in the United States and Canada. As of December 31, 2011, the Company’s estimated net proved reserves were 29.0 million barrels of oil equivalent (MMBoe), (including reserves attributable to its 34.7% equity interest in the proved reserves of Blue Eagle), of which 53% were classified as proved developed, 54% were oil and natural gas liquids (NGL’s) and 94% by PV-10 were operated.
Has AXAS Found The Bottom and Ready To Move Up? Find Out Here
Echo Therapeutics Inc (NASDAQ:ECTE) traded up on a volume of 3.18 million, higher than its standard daily volume. Shares have gained 14.68% to $3.36. Over the last twelve months, the stock has lost-67.69% and faced a worst price of $1.84. Echo Therapeutics, Inc. (Echo) is a transdermal medical device company. The Company is developing Prelude SkinPrep System (Prelude) as a technology to allow for painless and skin permeation that enable both needle-free drug delivery and analyte extraction. Utilizing this technology, the Company is developing its needle-free Symphony tCGM System (Symphony), as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM), system for use in hospital critical care units and for people with diabetes.
For How Long ECTE’s Gloss will Attract Investors? Find out via this report
DARA Biosciences Inc (NASDAQ:DARA) settled 3.53% higher at $0.502 on above-normal volume of 3.07M shares during the last trading day. The stock has its 12-month high at $1.20 and 52-week low price was $0.45. It traded in a range of $0.49 to $0.54 during the last trading day. DARA BioSciences, Inc. is a specialty pharmaceutical company focused on the development and commercialization of oncology treatment and supportive care pharmaceutical products. The Company has the exclusive United States marketing rights to its Soltamox (oral liquid tamoxifen). As of December 31, 2011, the Company continues to have an internal clinical development program for its two drug candidates, which cleared investigational new drug applications from the Food and Drug Administration (FDA), KRN5500 and DB959. Its KRN5500 is a non-narcotic/non-opioid for the treatment of neuropathic pain in patients with cancer. DB959 is a drug candidate for the treatment of type II diabetes and dyslipidemia. On January 17, 2012, the Company acquired Oncogenerix, Inc.
Why Should Investors Buy DARA After the Recent Fall? Just Go Here and Find Out
In the last trading session, North American Palladium Ltd (USA) (NYSEMKT:PAL) was down on high volume, trading at a volume of 2.88M versus its average daily volume of 2.28 million shares. At $10.452, the stock has attained market capitalization of 88.95 million. North American Palladium Ltd. (NAP) is a precious metals producer that has been operating its flagship Lac des Iles mine (LDI) located in Ontario, Canada. LDI is a primary producer of palladium. The Company is in the business of exploring and mining palladium, platinum, gold and certain base metals. The Company’s 100%-owned subsidiary is the Lac des Iles Mines Ltd. (LDI).
Why Should Investors Buy PAL After the Recent Fall? Just Go Here and Find Out
About Equity Observer:
Equity Observer delivers intra-day insights into the equities, tech and investment world. The website is a window into what’s going on in the business world and why.
EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more.
The disclaimer is to be read and fully understood before using our site, or joining our email list.
http://www.equityobserver.com/ has a no tolerance spam policy; we will not sell or re-distribute your email to any 3rd party. A If applicable, please also unsubscribe from the newsletter using the link at the bottom of the email if you no longer wish to receive our emails. We only send our newsletters to opt-in members.
PLEASE NOTE WELL: The http://www.equityobserver.com/" rel="nofollow" href="http://www.equityobserver.com/"> http://www.equityobserver.com/>
Employees and contributors are NOT registered as an Investment Adviser in any jurisdiction whatsoever.
Read Full Disclaimerat: http://www.equityobserver.com/
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)